Business
Result of AGM & Board change
Result of AGM & Board change.
About this update from Bioventix Plc
[{"type":"text","content":"\n \n Bioventix plc \n\n (\"Bioventix\" or the \"Company\") \n\n Result of AGM & Board change \n\nBioventix plc (ISDX: BVXP) announces that at its Annual General Meeting held\nyesterday resolutions 1, 2, 3, 5, 6 and 7 were duly passed.\n\nResolution 4, in respect of Kim Tan's re-election as a Non-Executive Director,\nwas not put to shareholders.\n\nAccordingly, Mr. Tan has left the Board with immediate effect.\n\nFor further information please contact:\n\nBioventix plc Chief Executive Officer Tel: 01252 728 001 \n \nPeter Harrison \n \nfinnCap Ltd Corporate Finance Tel: 020 7220 0500 \n \nGeoff Nash/Simon Hicks Corporate Broking \n \nTom Jenkins \n\nAbout Bioventix plc:\n\nBioventix (www.bioventix.com) specialises in the development and commercial\nsupply of high-affinity monoclonal antibodies with a primary focus on their\napplication in clinical diagnostics, such as in automated immunoassays used in\nblood testing. The antibodies created at Bioventix are generated in sheep and\nare of particular benefit where the target is present at low concentration and\nwhere conventional monoclonal or polyclonal antibodies have failed to produce a\nsuitable reagent. Bioventix currently offers a portfolio of antibodies to\ncustomers for both commercial use and R&D purposes, for the diagnosis or\nmonitoring of a broad range of conditions, including heart disease, cancer,\nfertility, thyroid function and drug abuse. Bioventix currently supplies\nantibody products and services to the majority of multinational clinical\ndiagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP)\nwere admitted to trading on PLUS-SX in April 2010.\n ","length":2295,"tagName":"div"}]